<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pravastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00175</strong>&#160; (APRD00328)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6&#8217;-hydroxyl group that does not require <i>in vivo</i> activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00175/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00175/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00175.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00175.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00175.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00175.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00175.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00175">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pravastatin Sodium </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000146/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000146/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: VWBQYTRBTXKKOG-NJUCWUMRNA-M</li>
              <li>Monoisotopic Mass: 446.228048149</li>
              <li>Average Mass: 446.5096</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000146">DBSALT000146</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Elisor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lipostat</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mevalotin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pravachol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pravaselect</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Selipran</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hydroxymethylglutaryl-coa-reductase-inhibitors">Hydroxymethylglutaryl-CoA Reductase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>81093-37-0</td></tr><tr><th>Weight</th><td>Average: 424.5277<br>Monoisotopic: 424.246103506</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>36</sub>O<sub>7</sub></td></tr><tr><th>InChI Key</th><td>TUZYXOIXSAXUGO-PZAWKZKUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Fatty Acids and Conjugates</td></tr><tr><th>Subclass</th><td>Carbocyclic Fatty Acids</td></tr><tr><th>Direct parent</th><td>Carbocyclic Fatty Acids</td></tr><tr><th>Alternative parents</th><td>Fatty Alcohols; Branched Fatty Acids; Beta Hydroxy Acids and Derivatives; Unsaturated Fatty Acids; Dicarboxylic Acids and Derivatives; Carboxylic Acid Esters; Secondary Alcohols; Carboxylic Acids; Polyamines; Ethers; Enolates</td></tr><tr><th>Substituents</th><td>beta-hydroxy acid; hydroxy acid; dicarboxylic acid derivative; secondary alcohol; carboxylic acid ester; enolate; ether; carboxylic acid; carboxylic acid derivative; polyamine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the carbocyclic fatty acids. These are fatty acids contaning a carbocylic ring .</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease. </td></tr><tr><th>Pharmacodynamics</th><td>The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease. </td></tr><tr><th>Mechanism of action</th><td>Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated <i>in vivo</i>. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.</td></tr><tr><th>Absorption</th><td>Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng&#8226;hr/mL. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>50% bound to human plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3&#945;-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound. </p></td></tr><tr><th>Route of elimination</th><td>Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes. </td></tr><tr><th>Half life</th><td>77 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD<sub>50</sub>= 12,000 mg/kg (orally in rat)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Pravastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00089?highlight%5Bcompounds%5D%5B%5D=DB00175&amp;highlight%5Bproteins%5D%5B%5D=DB00175">SMP00089</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Kinesin-like protein KIF6<br>Gene symbol: KIF6<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q6ZMV9" target="_blank">Q6ZMV9 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs20455" target="_blank">rs20455 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C Allele</td><td>Improved response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/18222353" target="_blank" title="Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ, Pfeffer MA, White TJ, Braunwald E, Shepherd J, Devlin JJ, Sacks FM: Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29;51(4):435-43.">18222353 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>3-hydroxy-3-methylglutaryl-coenzyme A reductase<br>Gene symbol: HMGCR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P04035" target="_blank">P04035 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs17244841" target="_blank">rs17244841 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T Allele</td><td>Reduced response to statin drugs</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/15199031" target="_blank" title="Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004 Jun 16;291(23):2821-7.">15199031 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
        <td><span class="wishart wishart-not-available">Not Available</span></td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          <span class="wishart wishart-not-available">Not Available</span> 
        </td>
        <td>
            <span class="wishart wishart-not-available">Not Available</span>
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb</li>
<li>Apotex corp</li>
<li>Dr reddys laboratories inc</li>
<li>Glenmark generics ltd</li>
<li>Lek pharmaceuticals dd</li>
<li>Lupin pharmaceuticals inc</li>
<li>Matrix laboratories ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva hrvatska doo</li>
<li>Ranbaxy laboratories ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li>International Laboratories Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.lek.si">Lek Pharmaceuticals Inc.</a></li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg, 20 mg, 40 mg, 80 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Pravachol 40 mg tablet</td><td>6.53USD</td><td>tablet</td></tr><tr><td>Pravachol 80 mg tablet</td><td>6.53USD</td><td>tablet</td></tr><tr><td>Pravastatin sodium 40 mg tablet</td><td>4.89USD</td><td>tablet</td></tr><tr><td>Pravastatin sodium 80 mg tablet</td><td>4.89USD</td><td>tablet</td></tr><tr><td>Pravachol 20 mg tablet</td><td>4.39USD</td><td>tablet</td></tr><tr><td>Pravachol 10 mg tablet</td><td>4.38USD</td><td>tablet</td></tr><tr><td>Pravastatin sodium 20 mg tablet</td><td>3.33USD</td><td>tablet</td></tr><tr><td>Pravastatin sodium 10 mg tablet</td><td>3.28USD</td><td>tablet</td></tr><tr><td>Apo-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Co Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Jamp-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Mint-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Mylan-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Novo-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Pms-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Pravachol 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Ran-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Ratio-Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Sandoz Pravastatin 40 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Apo-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Co Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Jamp-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Mint-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Mylan-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Novo-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Pms-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Pravachol 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Ran-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Ratio-Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Sandoz Pravastatin 20 mg Tablet</td><td>1.18USD</td><td>tablet</td></tr><tr><td>Apo-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Co Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Jamp-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Mint-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Mylan-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Novo-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Pms-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Pravachol 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Ran-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Ratio-Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr><tr><td>Sandoz Pravastatin 10 mg Tablet</td><td>1.0USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5622985</td><td>1994-10-22</td><td>2014-10-22</td></tr><tr><td>Canada</td><td>1323836</td><td>1993-11-02</td><td>2010-11-02</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>171.2 - 173&#176;C</td><td>MSDS</td></tr><tr><td>water solubility</td><td>Soluble </td><td>FDA label </td></tr><tr><td>logP</td><td>0.59 </td><td>FDA label </td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.42e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.23</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.65</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>4.21</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-2.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>124.29</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>113.6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>46.56</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, &#8220;Method for producing pravastatin precursor, ML-236B.&#8221; U.S. Patent US6204032, issued October, 1976.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6204032&amp;tbm=pts" target="_blank">US6204032 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li><span class="caps">FDA</span> label</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00893" target="_blank">D00893 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C01844" target="_blank">C01844 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54687" target="_blank">54687 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504851" target="_blank">46504851 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.49398.html" target="_blank">49398 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=20688" target="_blank">20688 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000550" target="_blank">DAP000550 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451089" target="_blank">PA451089 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2247008" target="_blank">2247008 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/pravast.htm" target="_blank">http://www.rxlist.com/cgi/generic/pravast.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/pravastatin.html" target="_blank">http://www.drugs.com/cdi/pravastatin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Pravastatin" target="_blank">Pravastatin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C10AA03<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C10#C10">C10 &#8212; LIPID MODIFYING AGENTS</a></li><li><a href="/atc/C10A#C10A">C10A &#8212; LIPID MODIFYING AGENTS, PLAIN</a></li><li><a href="/atc/C10AA#C10AA">C10AA &#8212; HMG CoA reductase inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:06.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00175.pdf?1265922809">show</a>(145 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00175.pdf?1374988346">show</a>(44 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08873">Boceprevir</a></td><td>Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored. </td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB00930">Colesevelam</a></td><td>Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>Substrates of organic anion transporters may increase levels of repaglinide. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid drastic changes in dietary habit.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>